GSK plc (NYSE:GSK) Shares Sold by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. cut its stake in GSK plc (NYSE:GSK - Free Report) by 22.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 319,703 shares of the pharmaceutical company's stock after selling 94,436 shares during the period. Cullen Frost Bankers Inc.'s holdings in GSK were worth $10,812,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Indiana Trust & Investment Management Co lifted its holdings in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after buying an additional 500 shares during the last quarter. Crews Bank & Trust purchased a new stake in GSK during the 4th quarter worth about $26,000. ST Germain D J Co. Inc. lifted its holdings in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 522 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after buying an additional 302 shares during the last quarter. Finally, Sierra Ocean LLC purchased a new stake in GSK during the 4th quarter worth about $32,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of GSK stock traded up $0.78 on Friday, hitting $40.08. The stock had a trading volume of 8,122,019 shares, compared to its average volume of 5,002,241. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The stock has a market cap of $83.07 billion, a price-to-earnings ratio of 25.21, a P/E/G ratio of 1.12 and a beta of 0.58. The company's 50 day moving average price is $35.47 and its 200 day moving average price is $37.14.

Remove Ads

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, research analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a $0.3932 dividend. This represents a $1.57 annualized dividend and a yield of 3.92%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is 98.74%.

Analysts Set New Price Targets

GSK has been the subject of a number of recent analyst reports. Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and decreased their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.